よむ、つかう、まなぶ。
資料3-1 ミコフェノール酸モフェチル (24 ページ)
出典
| 公開元URL | https://www.mhlw.go.jp/stf/shingi2/0000198856_00031.html |
| 出典情報 | 医療上の必要性の高い未承認薬・適応外薬検討会議（第57回 ） |
ページ画像
ダウンロードした画像を利用する際は「出典情報」を明記してください。
低解像度画像をダウンロード
プレーンテキスト
資料テキストはコンピュータによる自動処理で生成されており、完全に資料と一致しない場合があります。
テキストをコピーしてご利用いただく際は資料と付け合わせてご確認ください。
151: 813-20
20) Tashkin DP et al. Cyclophosphamide versus placebo in scleroderma lung disease. N Engl J Med
2006; 354: 2655-66
21) Fernández-Codina A et al. Treatment algorithms for systemic sclerosis according to experts.
Arthritis Rheumatol 2018; 70: 1820-8
22) Hoa S et al. Screening and management of subclinical interstitial lung disease in systemic
sclerosis: an international survey. Rheumatology 2022; 61: 3401-7
23) Jerjen R et al. Systemic sclerosis in adults. Part II: management and therapeutics. J Am Acad
Dermatol 2022; 87: 957-78
24) Rahaghi FF et al. Expert consensus on the management of systemic sclerosis-associated
interstitial lung disease. Respir Res 2023; 24: 6
25) Hoffmann-Vold AM et al. The identification and management of interstitial lung disease in
systemic sclerosis: evidence-based European consensus statements. Lancet Rheumatol 2020; 2:
e71-e83
26) Ma X et al. Efficacy of mycophenolate mofetil versus cyclophosphamide in systemic sclerosisrelated interstitial lung disease: a systematic review and meta-analysis. Clin Rheumatol 2021;
40: 3185-93
27) Treatment and prognosis of interstitial lung disease in systemic sclerosis (scleroderma). In
UpToDate. 2021
28) 呼吸器疾患
最新の薬物療法 2、克誠堂出版；2017
29) Zamora AC et al. Use of mycophenolate mofetil to treat scleroderma-associated interstitial lung
disease. Respir Med 2008; 102: 150-5
30) Gerbino AJ et al. Effect of mycophenolate mofetil on pulmonary function in sclerodermaassociated interstitial lung disease. Chest 2008; 133: 455-60
31) Koutroumpas A et al. Mycophenolate mofetil in systemic sclerosis-associated interstitial lung
disease. Clin Rheumatol 2010; 29: 1167-8
32) Simeón-Aznar CP et al. Effect of mycophenolate sodium in scleroderma-related interstitial lung
disease. Clin Rheumatol 2011; 30: 1393-8
33) Yilmaz N et al. Two-year experience with mycophenolate mofetil in patients with scleroderma
lung disease: a case series. Int J Rheum Dis 2014; 17: 923-8
34) Vanthuyne
M
et
al.
A
pilot
study
of
mycophenolate
mofetil
combined
to
intravenous methylprednisolone pulses and oral low-dose glucocorticoids in severe early
systemic sclerosis. Clin Exp Rheumatol 2007; 25: 287-92
35) Tzouvelekis A et al. Effect and safety of mycophenolate mofetil or sodium in systemic sclerosisassociated interstitial lung disease: a meta-analysis. Pulm Med 2012; 2012: 143637
36) 膠原病に伴う間質性肺疾患
診断と治療指針 2020. 日本呼吸器学会・日本リウマチ学
会; 2020: p90-102
24
20) Tashkin DP et al. Cyclophosphamide versus placebo in scleroderma lung disease. N Engl J Med
2006; 354: 2655-66
21) Fernández-Codina A et al. Treatment algorithms for systemic sclerosis according to experts.
Arthritis Rheumatol 2018; 70: 1820-8
22) Hoa S et al. Screening and management of subclinical interstitial lung disease in systemic
sclerosis: an international survey. Rheumatology 2022; 61: 3401-7
23) Jerjen R et al. Systemic sclerosis in adults. Part II: management and therapeutics. J Am Acad
Dermatol 2022; 87: 957-78
24) Rahaghi FF et al. Expert consensus on the management of systemic sclerosis-associated
interstitial lung disease. Respir Res 2023; 24: 6
25) Hoffmann-Vold AM et al. The identification and management of interstitial lung disease in
systemic sclerosis: evidence-based European consensus statements. Lancet Rheumatol 2020; 2:
e71-e83
26) Ma X et al. Efficacy of mycophenolate mofetil versus cyclophosphamide in systemic sclerosisrelated interstitial lung disease: a systematic review and meta-analysis. Clin Rheumatol 2021;
40: 3185-93
27) Treatment and prognosis of interstitial lung disease in systemic sclerosis (scleroderma). In
UpToDate. 2021
28) 呼吸器疾患
最新の薬物療法 2、克誠堂出版；2017
29) Zamora AC et al. Use of mycophenolate mofetil to treat scleroderma-associated interstitial lung
disease. Respir Med 2008; 102: 150-5
30) Gerbino AJ et al. Effect of mycophenolate mofetil on pulmonary function in sclerodermaassociated interstitial lung disease. Chest 2008; 133: 455-60
31) Koutroumpas A et al. Mycophenolate mofetil in systemic sclerosis-associated interstitial lung
disease. Clin Rheumatol 2010; 29: 1167-8
32) Simeón-Aznar CP et al. Effect of mycophenolate sodium in scleroderma-related interstitial lung
disease. Clin Rheumatol 2011; 30: 1393-8
33) Yilmaz N et al. Two-year experience with mycophenolate mofetil in patients with scleroderma
lung disease: a case series. Int J Rheum Dis 2014; 17: 923-8
34) Vanthuyne
M
et
al.
A
pilot
study
of
mycophenolate
mofetil
combined
to
intravenous methylprednisolone pulses and oral low-dose glucocorticoids in severe early
systemic sclerosis. Clin Exp Rheumatol 2007; 25: 287-92
35) Tzouvelekis A et al. Effect and safety of mycophenolate mofetil or sodium in systemic sclerosisassociated interstitial lung disease: a meta-analysis. Pulm Med 2012; 2012: 143637
36) 膠原病に伴う間質性肺疾患
診断と治療指針 2020. 日本呼吸器学会・日本リウマチ学
会; 2020: p90-102
24